Early research (Phase 1)Ended earlyNCT02588456
What this trial is testing
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
University of Pennsylvania 5